Merck KGaA stops its evobrutinib programme following failure in Phase III trial for Multiple Sclerosis.
Merck KGaA is dropping its BTK inhibitor evobrutinib several months after a Phase III disappointment. The termination comes as the company moves toward an R&D model driven primarily by licensing deals and optionality
“We have stopped the [evobrutinib] program – we are not going to explore any other option,” CEO Belén Garijo said during its full-year earnings call with the media. “We have to be very disciplined with our capital allocation, and now we will focus on the other assets that we have in Phase III to move them forward.”
The termination cost thecompany a one-off amount of €95 million in the fourth quarter of 2023, per an earnings presentation.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins